Gemcitabine/Platinum Containing Regimens as Preoperative Chemotherapy for Patients With Non Small Cell Lung Cancer

This study has been completed.
Sponsor:
Information provided by:
Eli Lilly and Company
ClinicalTrials.gov Identifier:
NCT00191230
First received: September 12, 2005
Last updated: January 24, 2007
Last verified: January 2007

September 12, 2005
January 24, 2007
September 2001
Not Provided
Complete pathological response
Same as current
Complete list of historical versions of study NCT00191230 on ClinicalTrials.gov Archive Site
Response rate, disease free survival, toxicity including pulmonary toxicity,operative mortality and quality of life.
Same as current
Not Provided
Not Provided
 
Gemcitabine/Platinum Containing Regimens as Preoperative Chemotherapy for Patients With Non Small Cell Lung Cancer
A Randomized Phase II Trial of Gemcitabine Containing Regimens (Gemcitabine/Carboplatin and Gemcitabine/ Cisplatin)When Used as Preoperative Chemotherapy for Patients With Stage I and II NSCLC

To study the efficacy and tolerability of gemcitabine/platinum chemotherapy in non small cell lung cancer

Not Provided
Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Carcinoma, Non Small Cell Lung
  • Drug: gemcitabine
  • Drug: carboplatin
  • Drug: cisplatin
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
70
July 2006
Not Provided

Inclusion Criteria:

  • Histologically of cytologically confirmed non small cell lung cancer
  • No prior chemotherapy or radiation
  • No prior malignancy

Exclusion Criteria:

  • Pregnant or breastfeeding
  • Serious concomitant systemic disorder
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00191230
5489, B9E-US-S236
Not Provided
Not Provided
Eli Lilly and Company
Not Provided
Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon-Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) Eli Lilly and Company
Eli Lilly and Company
January 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP